Neoantigen based dendritic cell therapeutic - Shenzhen Dengding Biopharma
Alternative Names: Neoantigen-based DC immune preparation - Shenzhen Dengding Biopharma; Personalized tumor neoantigen DC therapeutic immune preparation - Shenzhen Dengding BiopharmaLatest Information Update: 11 Oct 2023
At a glance
- Originator Shenzhen Dengding Biopharma
- Developer Shenzhen Dengding Biopharma; The First Affiliated Hospital of Nanchang University
- Class Antineoplastics; Cell therapies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Solid tumours
Most Recent Events
- 01 Apr 2023 Clinical trials in Solid tumours (Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease) in China (SC) (NCT05749627)
- 03 Mar 2023 Shenzhen Dengding Biopharma in collaboration with The First Affiliated Hospital of Nanchang University plans a clinical trial for Solid tumours (Inoperable/Unresectable, Second-line therapy, Late-stage disease) in China in April 2023 (SC) (NCT05749627)
- 03 Mar 2023 Preclinical trials in Solid tumours in China (SC) as of March 2023